Literature DB >> 11227211

Bcr-Abl and inhibition of apoptosis in chronic myelogenous leukemia cells.

J L Fernandez-Luna1.   

Abstract

Chronic myelogenous leukemia (CML) cells are highly resistant to apoptosis induced by chemotherapeutic drugs. The observation that production of Bcr-Abl is the initiating event in CML has focussed attention on the survival signals triggered by this oncogene. A number of signal transducers and transcription factors have been associated with the antiapoptotic phenotype of CML cells, some of which lead to the expression and/or activation of members of the Bcl-2 family of apoptosis modulators, such as Bcl-xL and Bad. In this article, recent advances in understanding the antiapoptotic pathways triggered by Bcr-Abl in CML cells, are discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11227211     DOI: 10.1023/a:1009623222534

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  8 in total

1.  Stromal cell-derived factor-1 chemokine gene variant in blood donors and chronic myelogenous leukemia patients.

Authors:  Carlos Eduardo Coral de Oliveira; Gabriela Gonçalves de Oliveira Cavassin; Aparecida de Lourdes Perim; Thiago Franco Nasser; Karen Brajão de Oliveira; Maria Helena Pelegrinelli Fungaro; Juliana Laino do Val Carneiro; Maria Angelica Ehara Watanabe
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

Review 2.  Redox regulation of cell survival.

Authors:  Dunyaporn Trachootham; Weiqin Lu; Marcia A Ogasawara; Rivera-Del Valle Nilsa; Peng Huang
Journal:  Antioxid Redox Signal       Date:  2008-08       Impact factor: 8.401

3.  Computational identification of micro-structural variations and their proteogenomic consequences in cancer.

Authors:  Yen-Yi Lin; Alexander Gawronski; Faraz Hach; Sujun Li; Ibrahim Numanagic; Iman Sarrafi; Swati Mishra; Andrew McPherson; Colin C Collins; Milan Radovich; Haixu Tang; S Cenk Sahinalp
Journal:  Bioinformatics       Date:  2018-05-15       Impact factor: 6.937

4.  deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data.

Authors:  Andrew McPherson; Fereydoun Hormozdiari; Abdalnasser Zayed; Ryan Giuliany; Gavin Ha; Mark G F Sun; Malachi Griffith; Alireza Heravi Moussavi; Janine Senz; Nataliya Melnyk; Marina Pacheco; Marco A Marra; Martin Hirst; Torsten O Nielsen; S Cenk Sahinalp; David Huntsman; Sohrab P Shah
Journal:  PLoS Comput Biol       Date:  2011-05-19       Impact factor: 4.475

5.  Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypes.

Authors:  Madalene A Earp; Rama Raghavan; Qian Li; Junqiang Dai; Stacey J Winham; Julie M Cunningham; Yanina Natanzon; Kimberly R Kalli; Xiaonan Hou; S John Weroha; Paul Haluska; Kate Lawrenson; Simon A Gayther; Chen Wang; Ellen L Goode; Brooke L Fridley
Journal:  Oncotarget       Date:  2017-07-18

6.  PYRROLO[1,2-b][1,2,5]BENZOTHIADIAZEPINES (PBTDs) induce apoptosis in K562 cells.

Authors:  Gabriella Marfe; Carla Di Stefano; Romano Silvestri; Elisabetta Abruzzese; Gianfranco Catalano; Livia Di Renzo; Giuseppe Filomeni; Ezio Giorda; Giuseppe La Regina; Emanuela Morgante; Maria Rosa Ciriolo; Matteo Antonio Russo; Sergio Amadori; Paola Sinibaldi-Salimei
Journal:  BMC Cancer       Date:  2007-11-09       Impact factor: 4.430

Review 7.  Druggable Biochemical Pathways and Potential Therapeutic Alternatives to Target Leukemic Stem Cells and Eliminate the Residual Disease in Chronic Myeloid Leukemia.

Authors:  Fabien Muselli; Jean-François Peyron; Didier Mary
Journal:  Int J Mol Sci       Date:  2019-11-10       Impact factor: 5.923

Review 8.  BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia.

Authors:  Gustavo P Amarante-Mendes; Aamir Rana; Tarcila Santos Datoguia; Nelson Hamerschlak; Gabriela Brumatti
Journal:  Pharmaceutics       Date:  2022-01-17       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.